GBL bill
This article was originally published in The Tan Sheet
Executive Summary
House passes the Hillary J. Farias Date-Rape Prevention Drug Act Oct. 12 by a vote of 423-1. The bill (HR 2130) would classify both gamma butyrolactone and gamma hydroxybutyric acid as controlled substances; it passed the House Commerce Committee by voice vote Aug. 5 (1"The Tan Sheet" Aug. 16, In Brief). Companion legislation introduced in the Senate by Spencer Abraham (R-Mich.) is expected to be the subject of a hearing in the next 10 to 14 days. GBL, sold as a dietary supplement, has been the subject of several FDA warnings; GHB is under scrutiny as a "date rape" drug
You may also be interested in...
GBL
Hillary J. Farias Date Rape Prevention Drug Act (HR 2130) passes the full House Commerce Committee by voice vote Aug. 5. The bill, which would classify both gamma butyrolactone and gamma hydroxybutyric acid as controlled substances, passed the Commerce/Health Subcommittee July 27 (1"The Tan Sheet" Aug. 2, p. 4). The bill should reach the House floor in the weeks following Labor Day. Sen. Spencer Abraham (R-Mich.) introduced companion legislation (S 1561) Aug. 5, which was referred to the Judiciary Committee
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands